These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32190910)

  • 1. Non-clinical characterization of the disposition of EMA401, a novel small molecule angiotensin II type 2 receptor (AT2R) antagonist.
    Murgasova R; Carreras ET; Suetterlin-Hachmann M; da Silva Torrao LR; Kittelmann M; Alexandra V; Fredenhagen A
    Biopharm Drug Dispos; 2020 Apr; 41(4-5):166-183. PubMed ID: 32190910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.
    Smith MT; Wyse BD; Edwards SR
    Pain Med; 2013 May; 14(5):692-705. PubMed ID: 23489258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies.
    Anand U; Yiangou Y; Sinisi M; Fox M; MacQuillan A; Quick T; Korchev YE; Bountra C; McCarthy T; Anand P
    Mol Pain; 2015 Jun; 11():38. PubMed ID: 26111701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the angiotensin II type 2 receptor AT
    Perryman R; Renziehausen A; Shaye H; Kostagianni AD; Tsiailanis AD; Thorne T; Chatziathanasiadou MV; Sivolapenko GB; El Mubarak MA; Han GW; Zarzycka B; Katritch V; Lebon G; Lo Nigro C; Lattanzio L; Morse SV; Choi JJ; O'Neill K; Kanaki Z; Klinakis A; Crook T; Cherezov V; Tzakos AG; Syed N
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2116289119. PubMed ID: 35917342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
    Rice ASC; Dworkin RH; McCarthy TD; Anand P; Bountra C; McCloud PI; Hill J; Cutter G; Kitson G; Desem N; Raff M;
    Lancet; 2014 May; 383(9929):1637-1647. PubMed ID: 24507377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMA401, an angiotensin II type 2 receptor antagonist blocks visceral hypersensitivity and colonic hyperpermeability in rat model of irritable bowel syndrome.
    Nozu T; Miyagishi S; Nozu R; Ishioh M; Takakusaki K; Okumura T
    J Pharmacol Sci; 2021 Jul; 146(3):121-124. PubMed ID: 34030794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain.
    Smith MT; Muralidharan A
    Expert Opin Ther Targets; 2015 Jan; 19(1):25-35. PubMed ID: 25315162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain.
    Keppel Hesselink JM; Schatman ME
    J Pain Res; 2017; 10():439-443. PubMed ID: 28255254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain.
    Rice AS; Smith MT
    Clin Pharmacol Ther; 2015 Feb; 97(2):128-30. PubMed ID: 25670516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.
    McCarthy T
    J Peripher Nerv Syst; 2014 Oct; 19 Suppl 2():S13-4. PubMed ID: 25269730
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs.
    Andersson SH; Lindgren A; Postlind H
    Drug Metab Dispos; 1998 Jun; 26(6):528-35. PubMed ID: 9616187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species differences in the biotransformation of an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist: the effects of distinct glucuronide metabolites on overall compound disposition.
    Shaffer CL; Gunduz M; Ryder TF; O'Connell TN
    Drug Metab Dispos; 2010 Feb; 38(2):292-301. PubMed ID: 19910512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
    Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey.
    Sonesson A; Koechling W; Stalewski J; Tankó LB; Rasmussen BB
    Drug Metab Dispos; 2011 Oct; 39(10):1895-903. PubMed ID: 21768273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor.
    Zhang D; Hanson R; Roongta V; Dischino DD; Gao Q; Sloan CP; Polson C; Keavy D; Zheng M; Mitroka J; Yeola S
    Curr Drug Metab; 2006 Dec; 7(8):883-96. PubMed ID: 17168689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats.
    Zhu J; Hu Y; Ho MK; Wong YH
    Xenobiotica; 2012 Nov; 42(11):1138-50. PubMed ID: 22642804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment.
    Zhang JYJ; Zhang J; Kiffe M; Walles M; Jin Y; Blanz J; Dayer J; Sanchez A; Zhang C; Zhang L; Huang Y; Oyang C
    Xenobiotica; 2022 Jan; 52(1):65-78. PubMed ID: 34761729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey.
    Musick TJ; Gohdes M; Duffy A; Erickson DA; Krieter PA
    Drug Metab Dispos; 2008 Feb; 36(2):241-51. PubMed ID: 17991767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.